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Introduction
Although different authors suggest that the B-lymphocyte
activating factor (BAFF) may be involved in the selective
loss of B-cell tolerance in human systemic lupus erythema-
tosus (SLE), the mechanisms responsible for the deregula-
tion of this molecule in SLE remain unclear [1-3].
Aims
To investigate any associations between regulatory
genetic polymorphisms of BAFF gene, disease suscept-
ibility and serum BAFF (s-BAFF) levels in Tunisian sys-
temic lupus (SLE) patients.
Methods
The case-control study included 124 SLE patients and 152
healthy controls. Three single nucleotide polymorphisms
(SNPs) (-2841 T>C, -2701 A>T and -871 C>T) in the 5’
regulatory region of the BAFF gene were explored by
PCR-RFLP [4]. s-BAFF levels were measured by ELISA
(R&D Systems).
Results
s-BAFF levels were elevated in SLE patients (1717,08 pg/ml)
and in anti-dsDNA positive antibodies patients (1948,28
pg/ml) compared to both controls (665,82 pg/ml, p<10-3)
and patients without anti-dsDNA antibodies (1281,51
pg/ml, p:0,007). In contrast, no correlation was found
between global disease activity registered in SLEDAI and
s-BAFF levels (p: 0.7). Furthermore, no association was
found between BAFF genotypes and susceptibility to SLE.
Single allele, genotype and haplotype association analyses
showed no significant association with s-BAFF values,
clinical features or SLEDAI score in SLE.
Conclusions
Polymorphisms in the regulatory region of the BAFF gene
do contribute neither to increased s-BAFF levels nor to
the susceptibility to SLE in Tunisian patients. Increased
s-BAFF levels in anti-dsDNA positive antibodies SLE
patients suggest the central role of this molecule in
the inflammatory process involving in autoantibodies
production.
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